Utility of the quasi‐monomorphic variation range in unresectable metastatic colorectal cancer patients
Authors:
Open Access
- 24 August 2018
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 109 (11) , 3411-3415
Abstract
Microsatellite Instability (MSI) status is an established predictive biomarker for the treatment of the anti‐programmed death 1 (PD‐1) antibody. The current approach to determine the MSI status in tumours requires matched normal DNA. Some mononucleotide microsatellite markers are known to have few variant alleles in both Caucasians and Asians. Therefore, the length of these microsatellite makers is almost confined within the quasi‐monomorphic variation range (QMVR). Considering the application of MSI testing for various types of cancers, a simple, sensitive and inexpensive method is desired. This study assessed the clinical utility of the QMVR for determining the MSI status in patients with unresectable metastatic colorectal cancer (mCRC). The study enrolled 435 patients with mCRC. The concordance of the MSI status in mCRC between the standard method using tumour DNA plus matched normal DNA and the testing method using only tumour DNA was evaluated. Eleven (2.5%) MSI‐high cases were detected by both the standard and testing methods. The sensitivity and specificity of the testing method were both 100%, indicating complete concordance between the methods. Among the mononucleotide markers, three and two patients showed discordance for NR‐21 and BAT‐25, respectively. Results from MSI testing with normal tissue indicated that four of five patients had rare germline variants outside the QMVR. For BAT‐26, NR‐24 and MONO‐27, all patients showed complete concordance. Using the QMVR, the MSI status of mCRC can be determined without matched normal DNA.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP18kk0205004)
- Merck Sharp and Dohme United Kingdom
This publication has 11 references indexed in Scilit:
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Clinical utility of quasimonomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in Japanese patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01.Journal of Clinical Oncology, 2017
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- A Five-marker Panel in a Multiplex PCR Accurately Detects Microsatellite Instability-high Colorectal Tumors Without Control DNADiagnostic Molecular Pathology, 2012
- An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal CancersPLOS ONE, 2010
- Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human TumorsJournal of Clinical Oncology, 2006
- Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite InstabilityJNCI: Journal of the National Cancer Institute, 2004
- Development of a Fluorescent Multiplex Assay for Detection of MSI‐High TumorsDisease Markers, 2004
- Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesisNature, 1993
- Microsatellite Instability in Cancer of the Proximal ColonScience, 1993